Recent articles
Warren Buffett's Berkshire Hathaway Dives Into Biotechnology
Warren Buffett's holding company has disclosed its first biotechnology investment.
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Patients with HER2-positive breast cancer could have a new treatment option from Seattle Genetics this summer.
Incyte's Fourth-Quarter Report Signals Better Times Ahead
Though the pharmaceutical company reported a big clinical trial failure last month, there are other reasons for optimism.
Teva Pharmaceutical Reports a Step Back in 2019
The fourth-quarter report wasn't great, but there are signs that a turnaround is underway.
CVS Health Just Beat Expectations and Raised Some
The growing healthcare conglomerate outperformed forecasts in the fourth quarter, and boosted its outlook for the year ahead.
Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye
Seattle Genetics posted eye-popping data from a study of patients given a combination of Padcev and Keytruda.
Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA
The Food and Drug Administration will expedite its review of capmatinib.
FDA Grants a Priority Review To Gilead Sciences' Cancer Therapy
Gilead's next cell-based therapy could become a new lymphoma treatment option this summer.
Allergan Reports Fourth-Quarter 2019 Results That Plow Past Expectations
The maker of Botox appears to be on an upswing just ahead of its megamerger with AbbVie.
AbbVie Reports Estimate-Beating Fourth-Quarter Earnings Results
Better than expected performances from new drugs and Humira gave investors plenty to look forward to in 2020.
GlaxoSmithKline Predicts a 2020 Loss, Prepares for Its Consumer Spinoff
The pharmaceutical giant's fourth-quarter 2019 earnings were disappointing, but there were things for investors to smile about in the new details on its upcoming spinoff.
Full Steam Ahead For Aimmune Therapeutics and the World's First Peanut Allergy Therapy
Another $200 million investment from Nestle will turbocharge Palforzia's commercial launch.
Tilray Is Restructuring and Laying Off Staff
One of Canada's largest cannabis producers is taking a big step back.
FDA Shines a Spotlight on Asbestos Testing for Talc Products
A rare public meeting to discuss the testing of personal care products for asbestos was informative and disturbing.
Aurora Cannabis Receives Another EU-GMP Certification
This more than triples the amount of medical marijuana that Aurora can export to Germany and the rest of the European Union.
3 Big Drugmakers Are Taking On the Coronavirus
Some of the biopharma industry's biggest names are taking important steps to combat the world's latest public health emergency.
5 Reasons Pfizer Is Big Pharma's Top Dividend Stock to Buy Right Now
Despite a poorly received fourth-quarter earnings report, Pfizer's the industry's best dividend-paying stock.
AbbVie's Acquisition of Allergan Gets Help From Nestle and AstraZeneca
A pair of deals will remove some regulatory impediments to the merger.
3 Biotech Start-Ups That Could Soar in 2020
Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.
An Emboldened Bristol-Myers Squibb Wants $1.5 Billion From Gilead Sciences
A jury that told Gilead Sciences to pay $752 million worth of patent infringement damages didn't go as far as necessary, says Bristol-Myers Squibb.